Safety Workshop: Part I Clinical Trial Safety and Safety Monitoring August 18, 2010 Albert Yoyin, M.D. DAIDS Regulatory Support Center (RSC) August 18,
Mary Ellen Turner MD, MPH Vice-President Global Safety Surveillance & Epidemiology Risk Management: Practical Implications for Pharmaceutical Manufacturers.
Safety Workshop: Part I Clinical Trial Safety and Safety Monitoring Ling Chin, MD, MPH NIAID/DAIDS/Office of Policy for Clinical Research Operations Durban,
Brenda Crowe, Research Advisor, Eli Lilly and Company With special thanks to Jesse Berlin
Meta-Analysis of Clinical Data for Regulated Biopharmaceutical Products: Answers to Frequently Asked Questions
DAIDS Safety Workshop: Part I Clinical Trial Safety and Safety Monitoring Albert Yoyin, M.D. and Anuradha Jasti, M.D. DAIDS Regulatory Support Center (RSC)
